ENTRY       D10745            Mixture   Drug
NAME        Ombitasvir, paritaprevir and ritonavir;
            Technivie (TN)
COMPONENT   (Ombitasvir hydrate [DR:D10598] | Ombitasvir [DR:D10576]), (Paritaprevir hydrate [DR:D10597] | Paritaprevir [DR:D10580]), Ritonavir [DR:D00427]
CLASS       Antiviral
             DG03198  Anti-HCV agent
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02925  CYP3A5 substrate
            Metabolizing enzyme inhibitor
             DG02852  CYP3A/CYP3A4 inhibitor
              DG01522  CYP3A4 inhibitor
            Transporter substrate
             DG01665  ABCB1 substrate
             DG01913  ABCG2 substrate
             DG02856  SLCO1B1 substrate
             DG02932  SLCO1B3 substrate
            Transporter inhibitor
             DG01622  ABCB1 inhibitor
             DG02862  ABCG2 inhibitor
             DG02865  SLCO1B1 inhibitor
             DG02907  SLCO1B3 inhibitor
REMARK      ATC code: J05AP53
EFFICACY    Antiviral
  DISEASE   Chronic hepatitis C virus infection [DS:H00413]
COMMENT     Paritaprevir is an inhibitor and a substrate of P-gp, BCRP and OATP1B1/1B3.
            Ombitasvir is metabolized by P-gp.
            Ritonavir is an inhibitor and a substrate of P-gp; it is also an inhibitor of CYP3A4 and BCRP.
TARGET      HCV NS3/4A protease [KO:K22273 K22274]
            HCV NS5A [KO:K22275]
            HIV protease [KO:K22599]
  PATHWAY   ko03230(K22273+K22274+K22275+K22599)  Viral genome structure
            ko03240(K22273+K22274+K22275)  Viral replication
            ko03250(K22599)  Viral life cycle - HIV-1
            ko05160(K22273+K22274+K22275)  Hepatitis C
METABOLISM  Enzyme: CYP3A4 [HSA:1576], CYP3A5 [HSA:1577]
            Transporter: ABCB1 [HSA:5243], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCG2 [HSA:9429]
INTERACTION CYP inhibition: CYP3A4 [HSA:1576]
            Transporter inhibition: ABCB1 [HSA:5243], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCG2 [HSA:9429]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AP Antivirals for treatment of HCV infections
                 J05AP53 Ombitasvir, paritaprevir and ritonavir
                  D10745  Ombitasvir, paritaprevir and ritonavir
            Drug groups [BR:br08330]
             Antiviral
              DG03198  Anti-HCV agent
               D10745  Ombitasvir, paritaprevir and ritonavir
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10745  Ombitasvir, paritaprevir and ritonavir
              DG02925  CYP3A5 substrate
               D10745  Ombitasvir, paritaprevir and ritonavir
             Metabolizing enzyme inhibitor
              DG02852  CYP3A/CYP3A4 inhibitor
               DG01522  CYP3A4 inhibitor
                D10745  Ombitasvir, paritaprevir and ritonavir
             Transporter substrate
              DG01665  ABCB1 substrate
               D10745  Ombitasvir, paritaprevir and ritonavir
              DG01913  ABCG2 substrate
               D10745  Ombitasvir, paritaprevir and ritonavir
              DG02856  SLCO1B1 substrate
               D10745  Ombitasvir, paritaprevir and ritonavir
              DG02932  SLCO1B3 substrate
               D10745  Ombitasvir, paritaprevir and ritonavir
             Transporter inhibitor
              DG01622  ABCB1 inhibitor
               D10745  Ombitasvir, paritaprevir and ritonavir
              DG02862  ABCG2 inhibitor
               D10745  Ombitasvir, paritaprevir and ritonavir
              DG02865  SLCO1B1 inhibitor
               D10745  Ombitasvir, paritaprevir and ritonavir
              DG02907  SLCO1B3 inhibitor
               D10745  Ombitasvir, paritaprevir and ritonavir
            Antimicrobials [BR:br08307]
             Antivirals
              Polyprotein cleavage inhibitor
               HCV NS3/4A inhibitor
                D10745  Ombitasvir, paritaprevir and ritonavir
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10745
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10745
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10745
             Drug transporters
              D10745
DBLINKS     PubChem: 254741706
            ChEBI: 90919
///
